Managers / Q3 2022 · view latest →
Krensavage Asset Management, LLC
CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582
Summary
Krensavage Asset Management, LLC reported $314M in U.S.-listed holdings across 14 positions for Q3 2022.
Its largest position, BIIB, represents 15.7% of the portfolio.
Compared with Q2 2022, the fund opened 1 new position and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 94.5% · $297M
- Other · 5.5% · $17M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VNDAVANDA PHARMACEUTICALS INC | NEW | +312.3K | 312.3K | +$3M | $3M |
| ASSEMBLY BIOSCIENCES INC | SOLD OUT | −10.0K | 0 | −$21,000 | $0 |
| CAHCARDINAL HEALTH INC | ADDED | +157.9K | 336.7K | +$13M | $22M |
| MCKMCKESSON CORP | TRIMMED | −51.0K | 31.9K | −$16M | $11M |
| BIIBBIOGEN INC | ADDED | +67.4K | 184.6K | +$25M | $49M |
| EXELEXELIXIS INC | ADDED | +314.6K | 1.82M | −$3M | $29M |
| KODKODIAK SCIENCES INC | TRIMMED | −84.8K | 469.4K | −$601,000 | $4M |
| ENTAENANTA PHARMACEUTICALS INC | TRIMMED | −35.4K | 589.4K | +$1M | $31M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | BIIBBIOGEN INChistory → | COM | 15.70% | $49M | 184.6K |
| 2 | UTHRUNITED THERAPEUTICS CORPhistory → | COM | 13.36% | $42M | 200.4K |
| 3 | REGNREGENERON PHARMACEUTICALShistory → | COM | 13.36% | $42M | 60.9K |
| 4 | ALKSALKERMES PLChistory → | COM | 10.04% | $32M | 1.41M |
| 5 | ENTAENANTA PHARMACEUTICALS INChistory → | COM | 9.73% | $31M | 589.4K |
| 6 | EMBCEMBECTA CORPhistory → | COM | 9.39% | $29M | 1.02M |
| 7 | EXELEXELIXIS INChistory → | COM | 9.09% | $29M | 1.82M |
| 8 | CAHCARDINAL HEALTH INChistory → | COM | 7.15% | $22M | 336.7K |
| 9 | TARO PHARMACEUTICAL INDUS | COM | 5.54% | $17M | 580.8K |
| 10 | MCKMCKESSON CORPhistory → | COM | 3.45% | $11M | 31.9K |
| 11 | KODKODIAK SCIENCES INChistory → | COM | 1.16% | $4M | 469.4K |
| 12 | EGRXEAGLE PHARMACEUTICALS INChistory → | COM | 1.02% | $3M | 121.1K |
| 13 | VNDAVANDA PHARMACEUTICALS INC | COM | 0.98% | $3M | 312.3K |
| 14 | NEXTCURE INC | COM | 0.03% | $86,000 | 31.3K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $256M | 20 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $283M | 18 | Feb 18, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $235M | 17 | Nov 17, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $189M | 15 | Aug 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $181M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $169M | 12 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2024 | $178M | 13 | Nov 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $218M | 13 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $226M | 12 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $282M | 12 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $272M | 12 | Nov 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $316M | 12 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $329M | 12 | May 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $324M | 12 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $314M | 14 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $302M | 14 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $290M | 13 | May 17, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $288M | 10 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $319M | 13 | Nov 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $295M | 13 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $289M | 12 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $342M | 12 | Feb 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $314M | 11 | Dec 8, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $368M | 11 | Aug 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2020 | $311M | 13 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $293M | 12 | Feb 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $260M | 10 | Nov 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $308M | 10 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $370M | 12 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.